← Back to Patent Explorer
US4155992A Expired / Lapsed US ⏱️ 0.0 years remaining

Pharmaceutical composition of poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality with drug

Assignee: Alza Corp
•
Filing: 1977-10-19
•
Granted: 1979-05-22
•
Expires: 1997-10-19
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers comprising (1) a repeating dioxycarbon unit in the polymeric backbone having a plurality of organic groups pendant therefrom, and (2) a bridging moiety having at least one carbonyloxy group contained therein are disclosed. The polymers are represented by the formula: <IMAGE> WHEREIN R is a bridging moiety and is either R1 or R2 arranged in a random manner along the polymeric backbone to form a copolymer containing both R1 and R2 with R1 an aliphatic, an alicyclic or an aromatic group and R2 is a <IMAGE> GROUP WITH R1 as defined and R3 an aliphatic, an alicyclic or aromatic group, or wherein R is a bridging moiety and is only R2 to form a homopolymer with R1, R2, and R3 as defined above, and a is 0 to 1, b is 2 to 6, and n and the sum of x and y are positive integers. The copolymers are useful for making articles of manufacture, including devices and coatings for delivering beneficial agents.

Inventors

  • 👤 Edward E. Schmitt

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 19:03
CPC Classifications
C; C08; C08G; C08G65/00; C08G65/34; A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; A61K9/204; C05; C05G; C05G5/00; C05G5/30; C05G5/37

Claims Analysis

Total Claims: 2
Claim 1
Independent Claim 250 words
A composition of matter comprising a homopolymer of the general formula: ##STR34## wherein R 1 is a member selected from the group consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene of 3 to 7 carbons substituted with a member selected from the group consisting of an alkyl of 1 to 10 carbons; alkenyl of 2 to 10 carbons, alkoxy of 1 to 10 carbons and alkylene of 1 to 10 carbons; cycloalkenylene of 5 to 7 carbons; cycloalkenylene of 5 to 7 carbons substituted with a member selected from the group consisting of an alkyl of 1 to 10 carbons, alkenyl of 2 to 10 carbons, alkoxy of 1 to 10 carbons and akylene of 1 to 10 carbons; arylene, arylene of 6 to 20 carbons substituted with an alkyl of 1 to 10 carbons, alkenyl of 2 to 10 carbons, alkoxy of 1 to 10 carbons and alkylene of 1 to 10 carbons; R 3 is the same as R 1 , a is 0 to 1, b is 2 to 6, n is 10 to 1000, ans x and y are 0 to 100 with at least one of x and y at least one, a drug dispersed in said homopolymer, and wherein the drug is released in a therapeutically effective amount at a controlled rate to an environment of use as the homopolymer erodes when in the environment over a prolonged period of time.
Claim 2
Dependent Claim 250 words
A composition of matter comprising a homopolymer of the general formula: ##STR34## wherein R 1 is a member selected from the group consisting of alkylene of 1 to 10 carbons; alkenylene of 2 to 10 carbons; cycloalkylene of 3 to 7 carbons; cycloalkylene of 3 to 7 carbons substituted with a member selected from the group consisting of an alkyl of 1 to 10 carbons; alkenyl of 2 to 10 carbons, alkoxy of 1 to 10 carbons and alkylene of 1 to 10 carbons; cycloalkenylene of 5 to 7 carbons; cycloalkenylene of 5 to 7 carbons substituted with a member selected from the group consisting of an alkyl of 1 to 10 carbons, alkenyl of 2 to 10 carbons, alkoxy of 1 to 10 carbons and akylene of 1 to 10 carbons; arylene, arylene of 6 to 20 carbons substituted with an alkyl of 1 to 10 carbons, alkenyl of 2 to 10 carbons, alkoxy of 1 to 10 carbons and alkylene of 1 to 10 carbons; R 3 is the same as R 1 , a is 0 to 1, b is 2 to 6, n is 10 to 1000, ans x and y are 0 to 100 with at least one of x and y at least one, a drug dispersed in said homopolymer, and wherein the drug is released in a therapeutically effective amount at a controlled rate to an environment of use as the homopolymer erodes when in the environment over a prolonged period of time.

References Cited (Backward Citations)

US3914402A Cited
US4001388A Cited
US3983209A Cited
US4093709A Cited
US4070347A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1982-05-21 1982-11-20 1983-05-22 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1986-05-21 1986-11-20 1987-05-22 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1990-05-21 1990-11-20 1991-05-22 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag